Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Interferon subtype gene therapy for regulating cytomegalovirus disease.

James CM, Bartlett EJ, Mansfield JP, Cull VS.

Methods Mol Med. 2005;116:207-19.

PMID:
16000864
2.

Type I IFN-beta gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis.

Bartlett EJ, Lenzo JC, Sivamoorthy S, Mansfield JP, Cull VS, James CM.

Immunol Cell Biol. 2004 Apr;82(2):119-26.

PMID:
15061762
3.

Cytokine expression in murine cytomegalovirus-induced myocarditis: modulation with interferon-alpha therapy.

Lenzo JC, Mansfield JP, Sivamoorthy S, Cull VS, James CM.

Cell Immunol. 2003 May;223(1):77-86.

PMID:
12914761
4.

Differential regulation of SOCS genes in normal and transformed erythroid cells.

Sarna MK, Ingley E, Busfield SJ, Cull VS, Lepere W, McCarthy DJ, Wright MJ, Palmer GA, Chappell D, Sayer MS, Alexander WS, Hilton DJ, Starr R, Watowich SS, Bittorf T, Klinken SP, Tilbrook PA.

Oncogene. 2003 May 22;22(21):3221-30.

5.

Optimization of Naked DNA Delivery for Interferon Subtype Immunotherapy in Cytomegalovirus Infection.

Bartlett EJ, Cull VS, Mowe EN, Mansfield JP, James CM.

Biol Proced Online. 2003;5:43-52. Epub 2003 Feb 17.

6.

Type I interferon differential therapy for erythroleukemia: specificity of STAT activation.

Cull VS, Tilbrook PA, Bartlett EJ, Brekalo NL, James CM.

Blood. 2003 Apr 1;101(7):2727-35. Epub 2002 Nov 21.

PMID:
12446459
7.

Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice.

Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM.

Gene Ther. 2002 Oct;9(20):1369-78.

8.

Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection.

Bartlett EJ, Cull VS, Brekalo NL, Lenzo JC, James CM.

Immunol Cell Biol. 2002 Oct;80(5):425-35.

PMID:
12225378
9.

Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Cull VS, Bartlett EJ, James CM.

Immunology. 2002 Jul;106(3):428-37.

10.

Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn.

Tilbrook PA, Palmer GA, Bittorf T, McCarthy DJ, Wright MJ, Sarna MK, Linnekin D, Cull VS, Williams JH, Ingley E, Schneider-Mergener J, Krystal G, Klinken SP.

Cancer Res. 2001 Mar 15;61(6):2453-8.

11.

Amiloride suppresses erythropoietin-induced proliferation and MAP kinase, but potentiates differentiation of J2E cells.

Callus B, Tilbrook PA, Busfield SJ, Cull VS, Bittorf T, Klinken SP.

Exp Cell Res. 1995 Jul;219(1):39-46.

PMID:
7543055
12.

Restriction fragment length polymorphisms of the human aldose reductase gene: a preliminary report.

Kicic E, Warren-Perry M, Cull VS, Wise PH, Chung S, Palmer TN.

Diabetes Res Clin Pract. 1993 May;20(2):165-8.

PMID:
8104111

Supplemental Content

Support Center